Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib and FLAG-IDA in relapsed/refractory AML
NCT04112589Phase 2Unknown
- Sponsor
- Fundación PETHEMA
- Start
- Dec 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of quizartinib in acute myeloid leukemia (AML), sponsored by Fundación PETHEMA. Status: unknown.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04112589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04112589.